Triple Negative Breast Cancers Activate Resistance Pathway to Evade Chemotherapy

Triple-negative breast cancers (TNBCs) are particularly aggressive, metastatic and resistant to chemotherapy treatments.  Researchers at the University of Texas MD Anderson Cancer Center have discovered that these cells alter epigenetic programing to temporarily become drug-resistant. The resistant cells switch metabolic pathways from...
Metastasis Infection

Triple Negative Breast Cancers Activate Resistance Pathway to Evade Chemotherapy

Triple-negative breast cancers (TNBCs) are particularly aggressive, metastatic and resistant to chemotherapy treatments.  Researchers at the University of Texas MD Anderson Cancer Center have discovered that these cells alter epigenetic programing to temporarily become drug-resistant. The resistant cells switch...
DNA mutation with green wrench twisting a red nut

Algorithm IDs Cancer Patients for Precision Treatments by Decoding Mutational Signatures

A new algorithm analyzes patterns in mutational profiles to identify cancer patients with underlying defects in DNA repair machinery, guiding targeted therapies.
Metastasis Infection

Triple Negative Breast Cancers Activate Resistance Pathway to Evade Chemotherapy

Triple-negative breast cancers (TNBCs) are particularly aggressive, metastatic and resistant to chemotherapy treatments.  Researchers at the University of Texas MD Anderson Cancer Center have discovered that these cells alter epigenetic programing to temporarily become drug-resistant. The resistant cells switch metabolic pathways from glycolysis to mitochondrial respiration, but a new...
Invatae logo

Non-Invasive Prenatal Screening Test

HDPCR Tick-Borne Pathogen (TBP) Panel is a multiplexPCR test that detects nine of the most common tick-borne pathogens in a single test.
CRISPR technology

Top 600 Cancer Drug Targets Ranked Using CRISPR

Researchers from the Wellcome Sanger Institute, GlaxoSmithKline, EMBL-EBI, and Open Targets conducted one of the largest CRISPR screens of cancer genes to date.

Sophia Genetics Gains CE-IVD Marking for Solid Tumor Solution

Sophia Genetics has obtained the CE-IVD marking for its Solid Tumor Solution (STS), a molecular diagnostic application designed to precisely detect and characterize all types of genomic alterations in 42 clinically relevant genes associated with a range of solid tumors. Those solid tumors include lung, colorectal, skin and brain cancers. According...

Stanford Studies Feasibility of AI Platform for Blood Cancer Precision Treatments

The AI platform from Notable completed personalized treatment recommendations for all 20 patients within 30 days demonstrating both a positive and negative predictive value average of 84 percent.
Colon cancer. Cancer attacking cell. Colon disease concept

CRC Evades Immunotherapies by Regulating Expression of Cell Surface Molecule

CRC tumors can switch off expression of a cell surface molecule that is a key target of immunotherapy, thus preventing the treatment from working.

DNAnexus, UPMC, Sutter Health Launch Clinico-Genomic MS Precision Medicine Study

Clinico-genomic research study aims to improve personalized treatments for people with multiple sclerosis DNAnexus, UPMC, and Sutter Health network said today they have launched a large-scale clinico-genomic multiple sclerosis (MS) research study aimed at improving personalized treatments for people with the group of 30+ inherited neuromuscular diseases. Under the collaboration, whose...

Thermo Fisher, NX Prenatal to Develop NIPT Proteomics Assays

Thermo Fisher Scientific will combine its liquid chromatography-mass spectrometry (LC-MS) instrumentation with NX Prenatal’s NeXosome platform to develop proteomics assays designed to offer noninvasive risk assessments of pregnancy outcomes, through a collaboration whose value was not disclosed. The collaboration aims to develop diagnostics to monitor fetal health in utero and...
3D DNA strands on a technology abstract background

Top 10 Sequencing Companies

Five years after the introduction of the $1,000 genome, the sequencing field remains rife with chatter about pushing the cost much lower—not only to $100 (and why the world may not be ready for it), but as far down as $10. Coming close to that $100 benchmark last year was Veritas Genetics....

Rethinking Rx-Dx Codevelopment

Sponsor: Molecular MD. Codevelopment is an intermittent and uncertain process. Adopting an agnostic approach to the challenges associated with platform and method selection provide added degrees of freedom for strategic development and selection of the most appropriate clinical trial assay.

Liquid Biopsy and ddPCR: A Match with Quality in Mind

Sponsor: Bio Rad. In this webinar we will hear how GenQA addresses some of the challenges in providing quality assessments for ctDNA testing.

Advancing Mass Spectrometry-Based Large-Cohort Proteomics for Precision Medicine

Sponsor: ThermoFisher Scientific. Large cohort studies are essential to the discovery of protein biomarkers, and their validation is indispensable to clinical utility.
Scroll Up